U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   Amendment No. 1
                                   to Form 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
OF 1934

For the quarter ended:   September 30, 2000

Commission file no. 0-24921

                         Surgical Safety Products, Inc.
                  --------------------------------------------
                 (Name of small business issuer in its charter)

          New York                                         65-0565144
-------------------------------                        -------------------
(State or other jurisdiction of                         (I.R.S. Employer
incorporation or organization)                          Identification No.)

         2018 Oak Terrace
        Sarasota, Florida                                    34231
---------------------------------------                   ----------
(Address of principal executive offices)                  (Zip Code)

Issuer's telephone number (941) 927-7874

Securities registered under Section 12(b) of the Exchange Act:

                                                  Name of each exchange on
      Title of each class                         which registered

               None
-----------------------------                     -------------------------

Securities registered under Section 12(g) of the Exchange Act:

                          Common Stock, $.001 par value
                       -----------------------------------
                                (Title of class)


Copies of Communications Sent to:

                                 Mercedes Travis, Esq.
                                 Mintmire & Associates
                                 265 Sunrise Avenue, Suite 204
                                 Palm Beach, FL 33480
                                 Tel: (561) 832-5696; Fax: (561) 659-5371




<PAGE>


Indicate by Check whether the issuer (1) filed all reports  required to be filed
by  Section  13 or 15(d) of the  Exchange  Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports),  and
(2) has been subject to such filing requirements for the past 90 days.

                   Yes     X        No
                          ---         ---

As of September  30, 2000,  there are  14,715,373  shares of voting stock of the
registrant issued and outstanding.














<PAGE>



                                     PART I

Item 1.            Financial Statements


Condensed Balance Sheets                                          F-1

Condensed Statements of Operations                                F-2

Condensed Statements of Cash Flows                                F-3

Notes to the Financial Statements                                 F-5















<PAGE>


<TABLE>
<CAPTION>
                         SURGICAL SAFETY PRODUCTS, INC.

                            CONDENSED BALANCE SHEETS

                                                                    (Unaudited)
                                                                     September                 December
                                                                        30,                      31,
                                                                       2000                      1999
                                                                 -----------------        --------------
<S>                                                             <C>                      <C>
                  Assets

Current Assets
  Cash and cash equivalents                                     $          376,765       $       516,799
  Accounts receivable                                                       14,760                17,086
  Prepaids and other                                                        84,682               118,569
                                                                 -----------------        --------------
    Total current assets                                                   476,207               652,454
                                                                 -----------------        --------------

Property and equipment, net                                                173,579               203,533
                                                                 -----------------        --------------

Other Assets
  Intangible assets, net                                                   459,652               270,487
  Software development costs, net                                          179,496               139,382
  Other assets                                                               9,750                10,250
                                                                 -----------------        --------------
    Total other assets                                                     648,898               420,119
                                                                 -----------------        --------------

Total Assets                                                    $        1,298,684       $     1,276,106
                                                                 =================        ==============


Liabilities and Stockholders' (Deficit)Equity

Current Liabilities
  Line of credit                                                $          100,000        $       100,000
  Notes payable - related parties                                           37,500                 52,500
  Deferred revenue                                                         150,000
  Accounts payable and accrued expenses                                    199,515                438,057
                                                                  ----------------         --------------
    Total current liabilities                                              487,015                590,557

Long-term Liabilities
   Notes payable                                                         1,091,026                650,000
                                                                  ----------------         --------------
    Total liabilities                                                    1,578,041              1,240,557
                                                                  ----------------         --------------

Stockholders' (Deficit) Equity
  Common stock, $.001 par value,
   100,000,000 shares authorized; 14,715,373 and 14,515,373
    shares issued and outstanding   in 2000 and 1999                        14,716                 14,516
   Common stock held in escrow                                             (2,076)                (2,700)
  Additional paid-in capital                                             3,527,968              2,804,020
  Accumulated deficit                                                  (3,819,965)            (2,780,287)
                                                                  ----------------         --------------
    Total stockholders' (deficit) equity                                 (279,357)                 35,549
                                                                  ----------------         --------------

Total Liabilities and Stockholders' (Deficit) Equity            $        1,298,684        $     1,276,106
                                                                  ================         ==============
</TABLE>


                     The accompanying notes are an integral
                       part of these financial statements.
                                      F-1-



<PAGE>



<TABLE>
<CAPTION>
                         SURGICAL SAFETY PRODUCTS, INC.

                       CONDENSED STATEMENTS OF OPERATIONS

                                  (UNAUDITED)



                                                 Nine Months Ended                      Three Months Ended
                                                   September 30,                           September 30,
                                               2000               1999                 2000               1999
                                         ----------------    --------------      ----------------    --------------
<S>                                     <C>                 <C>                 <C>                <C>
Revenue
   Net sales                            $               -   $           720     $               -  $            240
   License and production fees                    507,507           162,577                55,841           111,264
   Other income                                    10,534             1,924                 2,715               984
                                         ----------------    --------------      ----------------    --------------
    Total revenue                                 518,041           165,221                58,556           112,488
                                         ----------------    --------------      ----------------    --------------

Costs and expenses
  Cost of medical products sold                         -            14,271                     -             5,866
  Production and license fees                      50,437                 -                27,065                 -
  Operating expenses                            1,166,571           602,555               415,505           207,321
  Research and development expenses                44,431            40,287                11,250            20,202
  Interest expense                                237,082             9,755                25,385             2,315
  Loss on disposal of assets                       59,197                 -                59,197                 -
                                         ----------------    --------------      ----------------    --------------
    Total costs                                 1,557,718           666,868               538,402           235,704
                                         ----------------    --------------      ----------------    --------------

Net loss before income taxes                  (1,039,677)         (501,647)             (479,846)         (123,216)

Provision for income taxes

Net loss                                $     (1,039,677)   $     (501,647)     $       (479,846)  $      (123,216)
                                         ================    ==============      ================    ==============

Net loss per share                      $         (0.085)   $       (0.045)     $         (0.038)  $        (0.010)
                                         ================    ==============      ================    ==============
</TABLE>


                     The accompanying notes are an integral
                       part of these financial statements.
                                      F-2-













<PAGE>



<TABLE>
<CAPTION>
                         SURGICAL SAFETY PRODUCTS, INC.

                            STATEMENTS OF CASH FLOWS

              FOR THE NINE MONTHS ENDED SEPTEMBER 30, 200 AND 1999
                                   (UNAUDITED)
                                                                               Nine months ended
                                                                                 September 30,
                                                                         2000                     1999
                                                                  ------------------       ------------------
<S>                                                             <C>                       <C>
Cash Flows From Operating Activities
  Net loss                                                      $        (1,039,677)      $         (501,647)
                                                                  ------------------       ------------------
  Adjustments to reconcile net loss to cash
    used in operating activities
      Depreciation and amortization                                         200,007                   86,680
      Common stock issued for services and
           employee compensation                                             53,120                   41,303
      Stock option compensation expense                                       4,682                  (91,113)
       Interest expense - convertible debt                                  167,143
      Accrued interest added to notes payable                                59,468
      Loss on disposal of assets                                             59,197
      Decrease (increase) in operating assets
        Receivables                                                           2,326                  (14,559)
        Prepaids and other                                                   34,387
        Inventory                                                                 -                      654
      Increase (decrease) in operating liabilities
         Deferred revenue                                                   150,000                    6,874
        Accounts payable and accrued expenses                              (238,542)                  16,674
                                                                  ------------------       ------------------
          Total adjustments                                                 491,788                   46,513
                                                                  ------------------       ------------------
            Net cash used in operating activities                          (547,889)                (455,134)
                                                                  ------------------       ------------------

Cash Flows From Investing Activities
  Furniture and equipment purchased                                         (23,271)                 (93,239)
  Software development additions                                           (133,874)                 (57,348)
                                                                  ------------------       ------------------
    Net cash used in investing activities                                  (157,145)                (150,587)
                                                                  ------------------       ------------------

Cash Flows From Financing Activities
  Proceeds from related party loans                                               -                   77,500
  Proceeds from issuance of notes payable                                   650,000
  Deferred finance costs                                                    (70,000)
  Advances/(repayments) on line of credit, net                                    -                   50,000
  Repayment of stockholder loans                                            (15,000)                 (25,000)
  Proceeds from issuance of common stock                                          -                  475,000
                                                                  ------------------       ------------------
    Net cash provided by financing activities                               565,000                  577,500
                                                                  ------------------       ------------------

Net increase (decrease) in cash                                            (140,034)                 (28,221)
Cash and cash equivalents at beginning of year                              516,799                   41,191
                                                                  ------------------       ------------------
Cash and cash equivalents at end of year                        $           376,765      $            12,970
                                                                  ==================       ==================
</TABLE>


                     The accompanying notes are an integral
                       part of these financial statements.
                                      F-3-




<PAGE>





<TABLE>
<S>                                                             <C>               <C>
                                                                      2000               1999
                                                                  --------------    --------------
Supplemental Cash Flow Information:
  Cash paid for interest                                        $          7,496  $          5,474
                                                                  ==============    ==============
</TABLE>


For purposes of the statement of cash flows,  management  considers all deposits
and financial  instruments with original maturities of less than three months to
be cash and cash equivalents.

Material  non-cash  transactions  not  reflected in the  statement of cash flows
include:

For the Nine Months Ended September 30, 2000

- Deferred  financing  costs of $231,385  related to the issuance of warrants in
conjunction with the issuance of notes payable in March 2000

- Common  stock and  additional  paid in  capital  of  $268,442  issued  for the
conversion of notes payable


For the Nine Months Ended September 30, 1999
  The Company  received  fixed  assets in the amount of $58,700 for which it had
recorded deposits of such amount at December 31, 1998.























                     The accompanying notes are an integral
                       part of these financial statements.
                                      F-4-



<PAGE>



                         SURGICAL SAFETY PRODUCTS, INC.
                   Notes to Consolidated Financial Statements



Note 1 - Accounting Policies

Basis of Presentation

The condensed financial  statements of Surgical Safety Products,  Inc. (Company)
have been prepared  without audit,  pursuant to the rules and regulations of the
Securities and Exchange Commission. Certain information and footnote disclosures
normally included in financial  statements prepared in accordance with generally
accepted  accounting  principles have been condensed or omitted pursuant to such
rules and regulations. These consolidated financial statements should be read in
conjunction  with the financial  statements  and notes  thereto  included in the
Company's Annual Report on Form 10-KSB for the year ended December 31, 1999.

The results of operations for the nine month period ended September 30, 2000 are
not necessarily indicative of the results to be expected for any other period or
for the full year.

In the opinion of Company's  management,  the accompanying  unaudited  financial
statements  contain  all  adjustments,  consisting  of only  normally  recurring
adjustments,  necessary to present  fairly the financial  positions of September
30,  2000,  the results of  operations  and cash flows for the nine months ended
September 30, 2000 and September 30, 1999.

Net Loss Per Share

Net loss per share has been computed in accordance  with  Statement of Financial
Accounting  Standards (FASB) No. 128, "Earnings Per Share," by dividing net loss
by the weighted average number of shares outstanding  during the period.  Common
stock  equivalents have not been included in the computation of weighted average
number of shares outstanding since the effect would have been anti-dilutive.


Note 2 - Stock Compensation Expense

During fiscal year 1998, the Company issued stock options with an exercise price
that was below  market  price to  certain  of its  employees.  Accordingly,  the
Company recorded $91,113 of compensation expense related to the issuance for the
year ended December 31, 1998.

In the first  quarter of 1999,  the Company  canceled  these  stock  options and
issued  options with an exercise  price above that of market.  Accordingly,  the
Company  decreased its payroll expense by $91,113 for the  cancellation of these
options for the quarter ended March 31, 1999.

                                       F-5



<PAGE>


                         SURGICAL SAFETY PRODUCTS, INC.
                   Notes to Consolidated Financial Statements



Note 3 -Conversions of Debt

During the nine months ended  September 30, 2000,  the  investment  banking firm
that holds the notes payable related to the convertible line of credit,  elected
to Convert $268,442 of principal and interest outstanding into 624,617 shares of
common stock at prices  ranging  from $0.375 to $0.5625 per share.  These shares
were released from the shares held in escrow by the firm.

On October 24,  2000,  the firm  converted  another  $266,219 of  principal  and
interest into 709,918 shares of common stock at a price of $0.375 per share.

Note 4 - Commitments

On June  29,  2000,  the  Company  entered  into an  agreement  with a  clinical
organization to license various  components of its educational  material to host
on the Company's website for a three-year  period. The contract provides for the
Company to pay a base license fee of $117,000 per year,  plus additional fees on
the number of users that access the material on the Company's website. The total
amount of fees paid each year by the Company inclusive of both the basic license
fees and user fees are capped at $1,426,000.

On October 15, 2000, the financial  institution that holds the Company's line of
credit  extended  the maturity  date for such to December 31, 2000.  In order to
facilitate  this  extension,  the Company has  pledged  certificates  of deposit
totaling $50,000 against the line of credit.











                                       F-6








<PAGE>



Item 2. Management's Discussion and Analysis of Results of Operations.

General

     The Company's (OTC BB: SURG) overall mission is the research,  development,
production and distribution of innovative  products and services for healthcare.
Consisting  of both  traditional  products and  innovative  business-to-business
e-solutions,  the  common  goal is a safer and more  efficient  environment  for
healthcare workers,  manufacturers and patients.  Originally formed as a medical
device company,  Surgical shifted focus to being an e-company when the Company's
management recognized an untapped market niche:  responding to the critical need
for immediate communication and access to information in healthcare.

     Now, the Company operates two divisions  providing products and services to
the medical industry. The Information Systems Division,  formerly referred to as
Oasis@work,  through  its  Oasis  Information  Exchange  product  line  provides
business-to-business  on-demand  safety and  efficiency  driven  e-business  and
information for healthcare  workers.  The Medical Products and Services Division
develops, manufactures and distributes medical devices.

About Oasis Information Exchange

     The Oasis  Information  Exchange ("OIX") strategy is healthcare  e-business
content  aggregation  and  applications  integration  through a virtual  private
network.  It links the entire healthcare  continuum,  which includes  healthcare
workers,   administration,   patients,   and   healthcare   and   pharmaceutical
manufacturers.  Oasis Information Exchange is a true healthcare data center with
multiple  access  points.  It  is  an  Internet-based  virtual  private  network
consisting of points-of-access via intranets, the Internet, internet appliances,
and through  TouchPorts  located  throughout  healthcare  facilities  across the
country.  Although the Company is now focusing on providing its services through
the  Internet,   TouchPorts   remain   available  as  an  alternative   and  are
user-friendly   touch-access   internet   appliances   which  allow   healthcare
professionals  access to high quality  clinical  reference  and agency  mandated
information services.

     OIX consists of three lines of e-business.  The primary product produced by
OIX is a service that creates customized training applications for virtually any
topic. These web browser-based  educational  modules are designed to provide the
end-user with succinct,  current information on any topic within practically any
industry.  As a second  line of  business,  OIX builds  on-line  communities  in
specific target markets positioned as information  exchanges.  The third line of
business,  a  natural  by-product  of the first  two,  is  Internet  application
development and support services

     During the second  quarter of 2000,  the  Company  realized  that they were
focusing too much attention to the installation of hardware rather than focusing
its  attention  on its real  product -  information.  In July 2000,  the Company
signed an agreement with the  Association  of  periOperative  Registered  Nurses
("AORN"),  one of the largest  nursing  organizations  in the United States,  to
license their content - AORN Journal  Online,  OR Product  Directory,  Standards
Recommended  Practices and Guidelines  (SRPG) and other content.  See "Corporate
Developments".



<PAGE>



           AORN has 43,000  members and other  mailing  lists  comprising  of an
additional  100,000  people.  As part of this  initiative,  the Company  will be
producing  a CD-ROM  that  will be  mailed to  approximately  150,000  people in
December 2000. This CD-ROM will feature OASiS. The CD will be mailed in the AORN
Journal for members and as a separate mailing to others.

           Due  to  the   increase  and   availability   of  PC's  and  Internet
accessibility in the heathcare environment,  the Company realizes that, while in
some cases its OASiS network is needed in a particular environment, by an large,
its larger market is for its content. Essentially the Company is changing from a
hardware  network  supplier  to an  information  broker  which  will  create  an
information  exchange network for a defined healthcare  community that links the
end-users  to  the  industry  while  adding  value  to  both  parties.  This  is
essentially what the Company was doing all along; however, it had focused on the
delivery system for its product rather than the product itself.

           Under the AORN  arrangement,  the Company's product will be delivered
through the  Internet  via its  website or  information  exchange  which will be
called  OasisOR.com.  The data  center  will have the same type of content  from
device  manufacturers,  clinical  associations  and  other  relevant  resources;
however it will be for OR employees only, with the information relevant to them.

           Although the Company pays AORN a licensing  fee, the Company  expects
to  generate  revenue  from  sponsorships  of the  CD and  from  user  fees  and
advertising on its website.  The Company has  negotiated  its first  sponsorship
agreement with US Surgical in lieu of the previous
 agreement  which  required   massive expenditures for hardware installations.

           The Company  plans to scale the  concept  for other niche  markets by
creating websites that cater to a particular speciality.  The Company will focus
on providing website and intranet development.

Corporate Developments

           The  Company  entered  into an  agreement  with IBM  Global  Services
effective  January  3, 2000  which  included  an IBM  Customer  Agreement  and a
Statement  of Work  (the  "IBM  Global  Agreement").  Under the terms of the IBM
Global  Agreement  IBM agreed to provide  complete  implementation  and  support
service  solutions  for  1,200  OASiS  terminals  in an  estimated  400 end user
locations during the 12 month period commencing December 1, 1999. On February 3,
2000, IBM Global  Services and the Company  finalized the Statement of Work. The
services to be provided  under the agreement  included  project  planning,  site
surveys,  product  acquisition,   network  design,  web-site  hosting  services,
premises  wiring,  OASiS  TouchPort   Implementation,   help  desk  support  and
consulting   services.   The  estimated   cost  for   performing  the  work  was
approximately $10 million.  In addition,  IBM Global Services agreed to bill the
Company a monthly service charge for pre and post installation support services,
including 24-7 support,  and for labor,  travel and out of pocket expenses.  The
Company  was to  provide  technical  resources  and  oversee  the  IBM  Global's
activities.  Due to the new Internet focus, the Company has chosen to pursue for
the delivery of its product,  there is no longer any need for the services to be
provided by IBM. Effective July 14, 2000, this contract was terminated.



<PAGE>



           In February 2000, the Company executed an Investment Banking Services
Agreement  with  Dunwoody  Brokerage  Services Inc.  d/b/a Swartz  Institutional
Finance ("Swartz").  Under the agreement, Swartz agreed to introduce entities to
the  Company  for  potential  strategic  partnerships,  licensing  arrangements,
mergers, acquisitions,  investments or funding. For such services, Swartz was to
receive a scaled fee based upon the value of any completed transaction. Said fee
was payable in cash or stock at Swartz's option and by the issuance of warrants,
the number of which were to be based upon the fee divided by the market price of
the Company's  Common Stock.  There was no obligation on the part of the Company
to accept any transaction offered by the Swartz to the Company. Since no funding
was provided,  pursuant to the terms of the contract, the Company sent notice of
cancellation effective July 31, 2000.

           In February  2000, the Company  executed a Consulting  Agreement with
Global Development Advisors, Inc. ("GDA"); however, shortly thereafter,  further
negotiations  ensued  and  the  agreement  never  became  effective.  Under  the
agreement, GDA was to provide business and marketing consulting services, assist
in the implementation of a strategic plan and assist, coordinate and monitor the
Company's investor  relations  program.  The agreement was for a term of six (6)
months and could have been extended by the Company. In lieu of cash payments for
services, GDA agreed to accept 50,000 shares of the Company's Common Stock under
the Company's 2000 Stock Plan approved by its  shareholders on February 28, 2000
and options to  purchase an  additional  50,000  shares at an exercise  price of
$1.09. Due to the further negotiations, the issuance was never made. The parties
have canceled this Agreement.

           On February 29, 2000, the Company  entered into a contract with Steel
Beach Productions,  Inc. ("Steel Beach") to design, develop,  implement and test
the OASiS  Version  3.0 web based  application.  The  contract is for a total of
$160,100  and is to be paid  $80,500 in cash and $80,500 in stock  options.  The
Company paid a deposit of $20,012.50 and the balance is to be paid upon delivery
of the prototype,  preliminary product and final product. The options are due at
the time of delivery of the final  product.  The common stock option number will
be calculated  based on the average  closing share price  ("ACSP") in the twenty
(20) days of trading prior to deliver of the final  product.  The exercise price
will be 50% of the twenty  (20) day average  closing  price as quoted on the OTC
BB. The number of options issued will be calculated by multiplying $80,050 times
two (2) and  dividing  by the ACSP.  The  options are to have a term of five (5)
years  and are to  conform  to  Company's  consultant  option  policy  as far as
additional  terms and  details.  This  agreement  with Steel Beach  replaces two
earlier agreements;  specifically,  one agreement for Version 2.0 dated December
30, 1999 in the amount of $37,800 in cash and $37,800 in stock options,  and one
agreement  for Version 3.0 dated  December  30, 1999 in the amount of $42,250 in
cash  and  $42,250  in stock  options.  All  efforts  expended  by  Steel  Beach
Productions under these two earlier contracts are compensated under the terms of
this  agreement.  The Company retains all propriety  rights in the  application.
Steel Beach is responsible for its own costs and expenses.  The agreement may be
canceled by either  party on thirty (30) days  written  notice.  The product was
delivered and the parties are in the process of reconciling amounts owed between
them.

           On May 16, 2000,  the Company  entered  into a contract  with Horizon
Marketing Group ("Horizon") for the strategic  planning,  design and development
for sales and  marketing  presentations  by the  Company  and for the  Company's
website. The contract was amended on June 30, 2000. The initial contract was for
$18,300 which was increased in the amendment by $14,405,


<PAGE>



for a total  contract  price of $32,705 of which the  Company  has thus far paid
approximately  $14,000.  The contract is for a designated schedule of work which
is paid under a fee  schedule  and by a reward  bonus.  Under the reward  bonus,
Horizon  will,  as the last  payment,  receive the greater of 2% of the value of
each contract with a partner  secured by virtue of the work performed or $17,705
by  December  1, 2000.  Further,  Horizon  can be  engaged  to  provide  ongoing
development  services at the rate of $1000 per month.  The  contract  terminates
when the project is completed.

           On May 25, 2000, the Company  entered a staff leasing  agreement with
EPIX IV, Inc.  ("EPIX") as a  replacement  for  comparable  services  previously
provided  by  Staff  Leasing.  Like  the  Staff  Leasing  arrangement,  the EPIX
arrangment  creates a  co-employment  relationship  between EPIX and the Company
relative to the employees who work at the Company.

           Effective June 7, 2000, the Company's line of credit with  SouthTrust
renewed  through  August 12, 2000,  with an option to extend the maturity  until
October 15, 2000 if the Company  pledges a certificate  of deposit in the amount
of $25,000.  The interest rate is prime plus 1.5% and the line is secured by the
Company's  equipment,   receivables  and  inventory.   The  line  is  guaranteed
personally  by Dr. Swor.  The line of credit was renewed on October 15, 2000 and
the  maturity  date is December  31,  2000.  The Company  pledged an  additional
$25,000 certificate of deposit to secure the line. The outstanding amount on the
line is $100,000.

           Effective June 28, 2000,  the Company  negotiated a new contract with
US Surgical. This agreement supercedes all prior agreements between the parties.
Under the terms of the new agreement, US Surgical will pay through June 30, 2000
the Company $300,000 in settlement for all amounts owed to the Company under the
previous  agreements  and will pay the Company an additional sum of $200,000 for
future  services  under the  OasisOR.com  initiative.  This new  arrangement  is
principally due to the ineffective introduction by US Surgical of OASiS into the
healthcare  environment through hardware  installations.  Both companies realize
that the value of OASiS is the content and product it delivers. This new content
agreement  emphasizes US Surgical's continued belief in the information exchange
network which the Company now had embarked upon as its focus.

           Effective  July 1, 2000,  the Company  entered into an agreement with
AORN under  which AORN will  provide  certain  of its  proprietary  content on a
non-exclusive  license  basis to the  Company.  Under the  agreement,  AORN will
deliver to the Company  certain of its content for which it grants the Company a
non-exclusive  license to market and promote. The Company receives a substantial
credit toward advertising in the AORN Journal and other AORN  publications.  The
Company is required to provide the  software  and hardware to promote and market
the AORN  content.  The Company is required to pay AORN  $117,000 as the license
fee and contact  hours fee for the first year of the  agreement.  The Company is
required to pay one-half of the license fee by December 15, 2000.  To date,  the
Company has made payments  related to the license fee in the amount of $25,000.
AORN will reimburse the Company for certain conversion costs and to pay the cost
of web enabling  Home Study  Courses  sponsored by AORN.  The agreement is for a
term of three  (3)  years and it may be  terminated  by either  party on 180 day
notice. If terminated  without cause, the Company is entitled to a refund of any
unused  license  and user  fees.  AORN  retains  ownership  of its  intellectual
property  while the Company  retains  the  ownership  of its OASiS  intellectual
property.


<PAGE>



           On July 6, 2000,  the Company  entered into an agreement  with Carver
Cross  Securities  Corp.  ("CCSC") for investment  banking  services,  including
financial  advisory services and efforts to secure equity or debt financing.  TK
has given verbal approval for this arrangement, subject to final approval of any
financing  package.  The  CCSC  agreement  is  exclusive  for a term of 120 days
commencing the later of September 6, 2000 or the date a placement  memorandum is
ready for distribution. Under the agreement, CCSC receives a retainer of $6,000,
plus a warrant to purchase  40,000  shares of the  Company's  common stock for a
period of 5 years at an exercise price of $0.625 per share and monthly  payments
of $2,500 plus warrants for 40,000 shares of common stock..  In any case, under
the  agreement,  CCSC will not receive  warrants to purchase  more than  120,000
shares.  CCSC will receive  compensation for equity financing  arranged by CCSC,
the sale of assets or a public offering placement.  In the case equity financing
is arranged,  CCSC will receive complete warrants  exercisable for 5 years at an
exercise price equal to 101% of the amount paid by the  investors.  In addition,
CCSC receives approved  expenses.  This agreement has been terminated  effective
September 2000. No warrants have been issued related to this agreement; however,
the Company made payments to CCSC totaling $11,000.

     On August 16, 2000, the Company finalized a consulting  agreement with GDA.
Under  the  agreement,  GDA is to  provide  business  and  marketing  consulting
services,  assist  in  the  implementation  of  a  strategic  plan  and  assist,
coordinate and monitor the Company's investor  relations program.  The agreement
was for a term of three (3) months,  which term can be extended by the  Company.
In lieu of cash payments for services,  GDA agreed to accept  200,000  shares of
the Company's  Common Stock under the Company's  2000 Stock Plan approved by its
Shareholders  on February 28, 2000. On October 25, 2000, the Company  executed a
second agreement with GDA which, effectively, extends its initial agreement with
GDA for another  term of three (3)  months.  In lieu of cash  payments,  for its
services,  GDA agreed to accept an  additional  150,000  shares of the Company's
Common Stock under the Company's 2000 Stock Plan.

           In September  2000, the Company  entered into  agreements  with three
healthcare  companies  as sponsors  for its  AORN/OasisOR.com  CD-ROM  launch in
December  2000.  Sponsorships  range  from  $15,000 - $50,000  and  provide  the
companies  with  advertising  on the CD-ROM and AORN Journal ads, as well as the
production of in-service  Trainlets to be hosted on  OasisOR.com.  The companies
are  Haemacure  Corporation,   Imagyn  Medical  Technologies,   and  Karl  Storz
Corporation. In addition, the Company has entered into an agreement with Stryker
Corporation, another healthcare company, to produce in-service Trainlets for its
products.  The Trainlets will be hosted on OasisOR.com with links to the Stryker
website.  This  contract  is for  $32,500.  Each of these  contracts  are for a
one-year period.

           On  October 6, 2000,  the  Company  entered  into an  agreement  with
Quantumm  Internet  Services,  Inc.,("Quantumm"),  an Internet access  provider.
Under the terms of this agreement, Quantumm provides the Company with customized
Internet  services  that  enable the  Company to be a virtual  Internet  service
provider ("ISP").  Also,  Quantumm has contracted to design the Company's CD-ROM
for  OasisOR.com  that will be mailed out to AORN members in December  2000. The
CD- ROM will provide users the option to sign up for Internet  access branded as
OasisOR..com.  The total cost of the contract was $15,995  which the Company has
paid.



<PAGE>



           Effective October 15, 2000, the Company moved its corporate office to
3665 Bee Ridge Road,  Suite 300,  Sarasota,  Florida 34233.  The Company entered
into a six (6) month lease with two (2) renewal  options of six (6) months each.
The monthly rent is $3700, inclusive of common area maintenance.

           In December 1999, the Company  executed a Loan Agreement with Thomson
Kernaghan & Co.,  Ltd.  ("TK"),  as Agent and Lender,  whereby TK agreed to make
loans to the Company of up to $5,000,000 in installments for a period commencing
with the date of the  agreement  and ending on  November  30, 2002 (the "TK Loan
Commitment").  The Company may request additional draws of no less than $500,000
provided its Common  Stock has traded for a minimum of $1.00 for 20  consecutive
days and the stock has had an average  trading  volume of 25,000  shares for the
same period.  Due to the Company's  current share price, it does not qualify for
additional draws at this time.  Under the terms of the TK Loan Commitment,  each
installment  is supported by a convertible  note and security  agreement and the
Agent and Lender are granted warrants to purchase shares of the Company's Common
Stock.  Further,  2,700,000  shares are held by TK in escrow  for the  potential
conversion  under the notes or exercise of the warrants.  Under the terms of the
TK Loan Agreement, an initial loan of $650,000 was made on December 30, 1999. On
March 31, 2000 the Company received a second installment under the TK Commitment
in the amount of $650,000.  On April 28, 2000, TK elected to convert $100,000 of
outstanding  principal and $2,630 of the accrued  interest into shares of Common
Stock at a price of $0.5625 per share which represents  182,453 shares.  On June
9, 2000, TK elected to convert  $120,000 of outstanding  principal and $4,129 of
the accrued  interest into shares of Common Stock at a price of $0.375 per share
which represents 331,010 shares. On July 11, 2000, TK elected to convert $40,000
of  outstanding  principal and $1,683.13 of the accrued  interest into shares of
Common Stock at a price of $0.375 per share which represents  111,155 shares. On
October 24, 2000, TK elected to convert  $250,000 of  outstanding  principal and
$16,219 of the accrued interest into shares of Common Stock at a price of $0.375
per share which represents  709,918 shares.  The Company granted TK registration
rights  and was  obligated  to file a Form S-3  within  sixty  (60)  days of the
agreement.  The Company filed a  registration  statement on Form S-3 on March 2,
2000 covering  initially  20,038,097 shares of its Common Stock. The issuance of
the  securities  was made  pursuant  to  Regulation  S of the Act.  The Form S-3
registration  statement  was declared  effective  on April 11,  2000.  Since the
Company did not meet  financial  projections  which were an integral part of the
transaction,  TK and the Company are  re-negotiating  an arrangement which it is
anticipated  will be in the  form  of an  amendment  to the TK  Loan  Commitment
relative to future installments.

           The TK Loan  Commitment,  as draw  downs are  taken  and as  interest
accrues,  will  increase  the long  term debt of the  Company.  The  Company  is
currently  seeking other potential  funding.  With the TK Loan Commitment and in
the event  additional  debt is raised,  the Company will incur  future  interest
expense.  The TK Loan  Commitment,  if  fully  converted  and all  warrants  are
exercised,  will dilute the interest of existing  shareholders  and in the event
additional  equity is raised,  management may be required to dilute the interest
of existing  shareholders  further or forego a substantial interest in revenues,
if any. In the event that the Company is successful in securing  additional debt
financing,  the  amount  of such  financing,  depending  upon its  terms,  would
increase either the short or long term debt of the Company or both.




<PAGE>


Discussion and Analysis

           The  Company was  founded in 1992 to combat the  potential  spread of
bloodborne pathogenic infections such as HIV and hepatitis. It has broadened its
mission to  research,  develop,  manufacturing,  marketing  and selling  medical
products and services to the healthcare community.

           The  Company  was in the  development  stage until 1993 when it began
commercial  shipments of  SutureMate(R),  its first  product.  From inception in
June,  1992  through  December  31,  1999,  the  Company  generated  revenues of
approximately  $1,275,000  from a limited number of customers.  Since  inception
through  December  31,  1999,  the Company has  generated  cumulative  losses of
approximately  $2,780,000.  Although the Company has  experienced  a significant
percentage  growth in revenues from fiscal 1992 to fiscal 1999, the Company does
not believe  prior  growth rates are  indicative  of future  operating  results,
especially in light of the contract with AORN and its new  Internet-based  site,
OASiSOR.com and the anticipated contract with US Surgical.  Due to the Company's
operating history and limited  resources,  among other factors,  there can be no
assurance that  profitability  or significant  revenues on a quarterly or annual
basis will occur in the future.  Moreover,  the  Company  expects to continue to
incur operating losses through at least through fiscal 2000, and there can be no
assurance that losses will not continue after such date.

           As discussed  in the  independent  auditors'  report,  the  operating
losses  incurred by the  Company  raise doubt about its ability to continue as a
going concern. In addition,  with the implementation of its agreement with AORN,
and its new arrangement with US Surgical and/or with the establishment of one or
more  strategic  alliances  in  addition  to AORN and US  Surgical,  the Company
expects to  experience a period of growth,  which  requires it to  significantly
increase the scale of its operations.  This will result in significantly  higher
operating  expenses.  The  increase  in  operating  expenses  is  expected to be
partially funded by an increase in revenues. However, the Company's net loss may
continue  to  increase.  Expansion  of the  Company's  operations  may  cause  a
significant strain on the Company's  management,  financial and other resources.
The Company's ability to manage recent and any possible future growth, should it
occur,  will depend upon a  significant  expansion  of its sales and  marketing,
research and development,  accounting and other internal  management systems and
the  implementation  and  subsequent   improvement  of  a  variety  of  systems,
procedures and controls.  There can be no assurance that significant problems in
these areas will not occur.  Any failure to expand these areas and implement and
improve such systems,  procedures and controls in an efficient  manner at a pace
consistent with the Company's  business could have a material  adverse effect on
the Company's  business,  financial  condition and results of  operations.  As a
result of such expected expansion and the anticipated  increase in its operating
expenses,  as well as the difficulty in forecasting  revenue levels, the Company
expects to continue to  experience  significant  fluctuations  in its  revenues,
costs and gross margins, and therefore its results of operations.

           The  Company's  plan of  operations  for the next twelve months is to
focus  on  building   revenue  from  production  of  its  web-enabled   training
applications  called  Trainlets  that it is currently  marketing  to  healthcare
companies.  In addition, it anticipates additional revenues from the development
of its website  and  registered  user base.  The  Company  also is  aggressively
seeking   strategic   alliances   with  targeted   industry   partners  such  as
manufacturers  of  devices,   manufacturers  of  pharmaceuticals,   professional
organizations such as nursing associations and hospital group


<PAGE>



purchasing  organizations and integrated health networks along the lines created
with the AORN contract.

           The  Company  estimates  that  revenues  will be  sufficient  to fund
ongoing  operations at the current level when the website is functional  and its
registered  users  base  reach  levels of 75,000 or more.  The  Company  is also
aggressively  marketing its  web-enabled  Trainlets to healthcare  companies for
which it has already received contracts totaling approximately $350,000.

           In the short  term,  to fund  operations  through  fiscal  2000,  the
Company will seek to draw upon the funds available  under the TK Commitment,  to
seek  additional  funds from strategic  alliances with  potential  clients,  its
shareholders,  from additional third party financing or seek third party debt or
equity financing other than those planned by the current anticipated agreements.
Currently,  the Company has available its existing lines of credit.  The Company
has  increased  its staff from six (6) at fiscal 1999 year end to nine (9) as of
September  30,  2000.  Provided  that the TK  Commitment  and other  funding  is
available when needed,  the Company  believes that it can meet its capital needs
through year end.  There can be no assurance that the Company will be successful
in these efforts.

           As discussed in Note 10 to the Financial Statements, if the financing
referred to above is not  secured,  the  recoverability  of the  recorded  asset
amounts may be impaired.

           In 2001,  the  Company  will  require  between  $3 and $5  million in
additional capital in the form of debt or equity to fund the continued expansion
of the  Oasis  system  and its  development  to  meet  increased  demand  and to
implement its plans for increased marketing of its medical device products. This
reduction is due to the new  initiative  which is less  hardware  intensive  and
requires less maintenance. Under the TK Commitment, $3,700,000 remains available
under the terms of the  agreement  provided  the Company can  maintain its share
price. Other than the TK Commitment,  the Company has accepted no definite offer
from any other source.  There can be no assurance that such long-term  financing
will be  available  to the  Company or that it will be on terms that the Company
may seek.

Results of Operations for the Three and Nine Months Ended September 30, 2000 and
1999

Overview

           From its inception,  the Company has incurred losses from operations.
As of  September  30,  2000,  the Company  had  cumulative  net losses  totaling
approximately  $3,800,000.  During fiscal 1999,  management shifted its focus to
aggressively  marketing its proprietary  products,  especially  those associated
with Oasis Information Exchange.

Financial Position

           As of  September  30,  2000,  the  Company  had a deficit  of working
capital of $10,808,  as compared to a deficit of working  capital of $145,258 at
September  30, 1999.  This  decrease in deficit is primarily  due to  additional
borrowings on the TK Commitment and revenues received from US Surgical.


<PAGE>




Revenues

           For the nine months ended  September  30, 2000 and 1999,  the Company
had total revenues of $518,041 and $165,221,  respectively.  For the nine months
ended  September  30, 2000,  revenues  were  comprised  primarily of license and
production  fees  provided to US Surgical  pursuant to the  contract  dated July
1999.  For the three  months  ended  September  30,  2000 and 1999,  the Company
generated revenues of $58,556 and $112,488, respectively. Revenues for the three
months ended  September 30, 2000 consist of Trainlet  production and sponsorship
fees related to the Company's information exchange portal, OasisOR.com.  For the
three months ended September 30, 1999,  revenues were derived from the Company's
contract with US Surgical dated July 1999.

Selling, General, and Administrative Expenses

           For the nine months  ended  September  30, 2000,  operating  expenses
increased by $564,016 or 94% from  $602,555 for the nine months ended  September
30, 1999. This increase is primarily related to marketing  support  expenditures
to sustain the launch of the Company's Oasis Information Exchange. For the three
months ended September 30, 2000 and 1999,  operating expenses increased $208,184
from  $207,231  in 1999 to  $415,505  in 2000  due to  increased  personnel  and
marketing.  In  accordance  with the Company's  marketing  plan for fiscal 2000,
expenses  related to promotion,  trade shows,  and conventions were increased to
enhance the industry awareness of the company's products and services.

           In the past, the Company has focused on the design and development of
proprietary  products.  For fiscal 2000,  the Company has launched an aggressive
marketing  plan that is designed to increase  worldwide  sales of its  products.
Surgical believes that the increased operating expenses incurred during the nine
months ended September 30, 2000 will position the Company to generate  increased
revenue in the 2001 fiscal year.

Liquidity and Capital Resources

           The  financial  condition,  liquidity  and capital  resources  of the
Company  should be  assessed  in  context  with the  ability  of the  Company to
continue as a going concern as discussed in the independent auditors' report.

           The  Company's   operations  have  been  funded  primarily  from  the
$1,300,000  proceeds  of draw downs  under the TK  Commitment  completed  in the
fourth quarter 1999 and from cash flow of approximately  $500,000 from licensing
and  production  fees from US Surgical  for Oasis  during the nine months  ended
September 30, 2000.  This allowed the Company to enhance its Oasis  software and
data base and fund current operations.  At September 30, 2000, the Company has a
$376,765 cash position.

           In  addition  to the  balance of  $3,700,000  available  under the TK
Commitment,  the  Company  has a line of credit in the amount of  $100,000  that
matured on October 15, 2000 and has been renewed  through  December 31, 2000. It
is guaranteed by Dr. Swor. In the past, the line of credit also has been used to
fund operations on a short-term basis and $100,000 is currently


<PAGE>



outstanding.  As of September 30, 2000,  the Company  pledged a  certificate  of
deposit in the amount of  $25,000 to secure the line of credit.  On October  15,
2000, the Company pledged an additional  certificate of deposit in the amount of
$25,000 to renew the line of credit through December 31, 2000.

           Net cash used for investing  for the nine months ended  September 30,
2000 was  approximately  $157,000,  representing  primarily  enhancements to the
current version of Oasis.

           In the short term, to fund  operations  through the balance of fiscal
2000,  the Company will be required to make  additional  draw downs under the TK
Commitment,  seek  additional  funds from  strategic  alliances  with  potential
clients,  its shareholders,  from additional third party financing or seek third
party  debt  or  equity  financing  other  than  those  planned  by the  current
agreements. Additionally, the Company anticipates that revenues will begin to be
generated in the third and fourth  quarter of 2000 and that such  revenues  will
help to fund  operations.  Provided  that  additional  funding is  secured,  the
Company  believes that it can meet its capital needs through year end. There can
be no assurance that the Company will be successful in these efforts.

Forward-Looking Statements

           This Form 10-QSB  includes  "forward-looking  statements"  within the
meaning of Section 27A of the  Securities  Act of 1933, as amended,  and Section
21E of the Securities  Exchange Act of 1934, as amended.  All statements,  other
than  statements of historical  facts,  included or incorporated by reference in
this Form 10-QSB which  address  activities,  events or  developments  which the
Company expects or anticipates  will or may occur in the future,  including such
things as future capital expenditures (including the amount and nature thereof),
demand for the  Company's  products and  services,  expansion  and growth of the
Company's  business and operations,  and other such matters are  forward-looking
statements.  These statements are based on certain assumptions and analyses made
by the  Company in light of its  experience  and its  perception  of  historical
trends,  current  conditions and expected  future  developments as well as other
factors it believes  are  appropriate  in the  circumstances.  However,  whether
actual results or developments will conform with the Company's  expectations and
predictions is subject to a number of risks and uncertainties,  general economic
market and business  conditions;  the business  opportunities  (or lack thereof)
that  may be  presented  to and  pursued  by the  Company;  changes  in  laws or
regulation;  and other  factors,  most of which are  beyond  the  control of the
Company.  Consequently,  all of the forward-looking statements made in this Form
10-QSB  are  qualified  by  these  cautionary  statements  and  there  can be no
assurance  that the actual  results or  developments  anticipated by the Company
will be realized  or, even if  substantially  realized,  that they will have the
expected consequence to or effects on the Company or its business or operations.

                                     PART II

Item 1.  Legal Proceedings.

           The Company knows of no legal  proceedings  to which it is a party or
to which any of its property is the subject,  which are pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.


<PAGE>



Item 2. Changes in Securities and Use of Proceeds

           At a  meeting  of the  Board of  Directors  held on June 6,  2000,  a
resolution  was passed to modify the Company's 2000 Stock Option and Awards Plan
by providing of the 10,000,000  shares  authorized  under the plan,  that in any
calendar year,  options and awards to acquire no more than 1,000,000 shares will
be granted.

           Further,  at  the  same  meeting,  the  Board  adopted  a  resolution
regarding lock-up  provisions on holders of existing options and approved a form
of voluntary restriction agreement.  Under this arrangement,  certain holders of
such  options,  particularly  current and certain prior members of the Board and
current  and certain  prior  officers  of the  Company,  have agreed to specific
lock-up  provisions  which  restrict  resale and provide for the  placement of a
legend upon their shares  acquired under the options  granted under the plans in
force in 1994,  1998,  and  1999.  Voluntary  restriction  agreements  have been
executed by the parties to which it applied.

Item 3.  Defaults in Senior Securities

           None

Item 4. Submission of Matters to a Vote of Security Holders.

           No matters were  submitted to the Security  Holders for a vote during
the quarter ended September 30, 2000.

Item 5. Other Information

           None

Item 6.  Exhibits and Reports on Form 8-K

     (a)  The exhibits  required to be filed  herewith by Item 601 of Regulation
          S-B, as described in the following index of exhibits, are incorporated
          herein by reference, as follows:

<TABLE>
<S>            <C>
Exhibit No.    Description
-----------    -----------------------------------------------------------------

3.(I).1        Articles of Incorporation of Surgical Safety Products, Inc., a Florida corporation
               filed May 15, 1992 [1]

3.(II).1       Bylaws of Sheffeld Acres, Inc., now known as Surgical Safety Products, Inc. [1]

3.(II).2       Amended Bylaws of Surgical Safety Products, Inc. [2]

4.1            Voluntary Restriction Agreement between the Company and holders of Options
               under the 1994, 1998 and 1999 Stock Option Plan [10]
</TABLE>


<PAGE>


<TABLE>
<S>            <C>
10.1           Acquisition of Endex Systems, Inc. d/b/a/ InterActive PIE dated December 8, 1997
               [1]

10.2           Prepaid Capital Lease Agreement with Community Health Corporation relative to
               Sarasota Medical Hospital OASiS Installation dated January 30, 1998 [1]

10.3           Letter of Intent with United States Surgical Corporation dated February 12, 1998 [1]

10.4           Form of Rockford Industries, Inc. Rental Agreement and Equipment Schedule to
               Master Lease Agreement [1]

10.5           Ad-Vantagenet Letter of Intent dated June 19, 1998 [1]

10.6           Distribution Agreement with Morrison International Inc. dated September 30, 1996
               [1]

10.7           Distribution Agreement with Hospital News dated August 1, 1997 [1]

10.8           Clinical Products Testing Agreement with Sarasota Memorial Hospital dated January
               30, 1998 [1]

10.9           Real Estate Lease for Executive Offices effective June 1, 1998 [1]

10.10          Employment Agreement with Donald K. Lawrence dated April 1, 1997 [1]

10.11          Employment Agreement with G. Michael Swor dated June 15, 1998 [1]

10.12          Employment Agreement with Frank M. Clark dated June 15, 1998 [1]

10.13          Agreement for Consulting Services with Stockstowatch.com Inc. dated March 30,
               1988 [1]

10.14          Form of Employee Option Agreement dated July 1994 [1]

10.15          Form of Employee Option Agreement dated 1998 [1]

10.16          Form of Consultants Option Agreement dated July 1994 [1]

10.17          Form of Consultants Option Agreement dated 1998 [1]

10.18          Confidential Private Offering Memorandum dated May 30, 1995 [1]

10.19          Supplement to Private Offering Memorandum dated October 30, 1995 [1]

10.20          Stock Option Agreement with Bay Breeze Enterprises LLC dated April 9, 1998 [1]
</TABLE>



<PAGE>


<TABLE>
<S>            <C>
10.21          Revolving Loan Agreement, Revolving Note, Security Agreement with SouthTrust
               Bank dated May 2, 1997 [1]

10.22          Agreement between the Company and T. T. Communications, Inc. dated October 15,
               1998 [2]

10.23          Agreement between the Company and U.S. Surgical Corporation dated October 28,
               1998. [2]

10.24          Collaborative Agreement between the Company and Dr. William B. Saye dated
               November 16, 1998. [2]

10.25          Kiosk Information System, Inc. Purchase Order dated November 3, 1998 [2]

10.26          Surgical Safety Products 1999 Stock Option Plan adopted January 1999 [2]

10.27          Form of the Employee Option Agreement under the Surgical Safety Products 1999
               Stock Option Plan dated January 1999 [2]

10.28          Form of the Director, Consultant and Advisor Option Agreement under the Surgical
               Safety Products 1999 Stock Option Plan dated January 1999 [2]

10.29          Verio, Inc. Access Service Agreement dated February 16, 1999. [2]

10.30          Form of Investor Subscription Documents and Agreements relative to the April 1999
               Self Directed Private Placement Offering under Rule 506 of Regulation D. [3]

10.31          Form of the Warrant issued pursuant to the April 1999 Self Directed Private
               Placement Offering under Rule 506 of Regulation D. [3]

10.32          Consulting Agreement dated April 1999 with Koritz Group, LLC. [3]

10.33          Agreement dated April 1999 with KJS Investment Corporation. [4]

10.34          Agreement dated May 1999 with Ten Peaks Capital Corp. [4]

10.35          Private Partner Network Agreement dated July 30, 1999 with US Surgical [5]

10.36          Staff/Client Leasing Agreement dated October 16, 1999, as amended September 15,
               1999 [5]

10.37          Agreement dated July 15, 1999 with Triton Capital Inc.[6]

10.38          Effective December 30, 1999, Loan Agreement, Note, Security Agreement, Lender's
               Warrant, Agent's Warrant, Registration Rights Agreement and Escrow Agreement
               relative to the December 1999 transaction with Thomson Kernaghan & Co., Inc.  and
               Amendment thereto. [7]
</TABLE>


<PAGE>




<TABLE>
<S>            <C>
10.39          Effective January 3, 2000 IBM Customer Agreement and Statement of Work. [7]

10.40          Investment Banking Services Agreement dated February 2, 2000 with Dunwoody
               Brokerage Services Inc. [8]

10.41          Consulting Agreement dated February 15, 2000 with Global Development Advisors
               Inc. [8]

10.42          Surgical Safety Products 2000 Stock Option and Award Plan [8]

10.43          Agreement with Steel Beach Productions dated February 29, 2000 [9].

10.44          Agreement with Horizon Marketing Group dated May 16, 2000 [10]

10.45          Agreement with EPIX dated May 25, 2000 [10]

10.46          Amendment to the Company's 2000 Stock Option and Awards Plan dated June 6,
               2000 [10]

10.47          Revolving Loan Agreement, Revolving Note, Security Agreement with SouthTrust
               Bank dated June 7, 2000 [10]

10.48          Agreement with AORN effective July 1, 2000 [10]

10.49          Agreement with Carver Cross dated July 6, 2000 [10]

10.50          Agreement with U.S. Surgical effective June 28, 2000 [11]

10.51          Agreement with Imagyn dated September 18, 2000

10.52          Agreement with Haemacure dated September 19, 2000

10.53          Agreement with Storz dated September 29, 2000

10.54          Agreement with Quantum dated October 6, 2000

10.55          Agreement with Stryker dated October 9, 2000

10.56          Property Lease dated October 13, 2000

10.57          Agreement with GDA dated October 25, 2000

13.1           Definitive Proxy Statement filed February 28, 2000 [8]

27.1           Financial Data Sheet
----------------
</TABLE>



<PAGE>




[1]  Previously filed with the Company's Form 10SB

[2]  Previously filed with the Company's Amendment No. 1 to the Form 10SB

[3]  Previously  filed with the Company's Form 10QSB for the Quarter ended March
     30, 1999

[4]  Previously  filed with the Company's  Form 10QSB for the Quarter ended June
     30, 1999

[5]  Previously filed with the Company's Amendment No. 2 to the Form 10SB

[6]  Previously  filed  with the  Company's  Form  10QSB for the  Quarter  ended
     September 30, 1999

[7]  Previously filed with the Company's Form S-3 on March 2, 2000.

[8]  Previously  filed with the  Company's  Form 10KSB for the fiscal year ended
     December 31, 1999.

[9]  Previously  filed with the Company's Form 10QSB for the Quarter ended March
     31, 2000.

[10] Previously  filed with the Company's  Form 10QSB for the Quarter ended June
     30, 2000.

[11] Previously  filed with the Company's  Amendment 3 to the Form 10QSB for the
     Quarter ended June 30, 2000.

*    Filed herewith

     (b) No Reports on Form 8-K were filed  during the quarter  ended  September
30, 2000.


<PAGE>




                                   SIGNATURES

      In accordance with Section 12 of the Securities  Exchange Act of 1934, the
registrant caused this Registration  Statement to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                     Surgical Safety Products, Inc. (Registrant)

Date: January 4, 2001                 By:/s/ Pauline J. Parrish
                                     ---------------------------------------
                                     Pauline J. Parrish, Acting Chief
                                     Financial Officer